Similar Search Results

Improving data on pharmaceutical expenditure in hospitals and other health care settings

Morgan, David - 2022

As a key component of health care, a full understanding of how much is spent on prescription medicines is increasingly important. Only a partial understanding of total expenditures across health systems is currently possible, as reporting is often limited to medicines dispensed in community...

Persistent link: https://www.econbiz.de/10013202471

An Unnecessary Proposal : A WTO Waiver of Intellectual Property Rights for COVID-19 Vaccines

Baachus, James - 2021

In a sign of their increasing frustration with global efforts to ensure that all people everywhere will have access to COVID-19 vaccines, several developing countries have asked other members of the World Trade Organization (WTO) to join them in a sweeping waiver of the intellectual property...

Persistent link: https://www.econbiz.de/10013248992

An Ounce of Prevention or a Pound of Cure? Short- and Long-Run Effects of Pharmaceutical Patents on U.S. Health Care Expenditures

Johnson, Hilary S.; Johnson, Daniel K. N. - 2014

This study examines the relationship between pharmaceutical R&D and health care expenditures, distinguishing between the short- and long-run impacts. To measure these relationships quantitatively, we focus on patents as a key factor driving the costs of pharmaceuticals, and develop a structured...

Persistent link: https://www.econbiz.de/10014209235

Biologic Drugs, Biosimilars, and Barriers to Entry

Shepherd, Joanna - 2014

Biologic drugs represent an important category of drugs that improve health outcomes in this country. Yet, these cutting-edge drugs are often prohibitively costly, preventing access for many Americans. Recognizing the need for more affordable, generic substitutes for biologic drugs — or...

Persistent link: https://www.econbiz.de/10014148056

Canada's Patented Medicines (Notice of Compliance) Regulations : Removing Inefficiencies to Encourage Generic Competition

Porter, Suzanne - 2013

Canada's Patented Medicines (Notice Of Compliance) Regulations fail to achieve the intended purpose of balancing innovation with timely generic market entry. An examination of the inefficiencies created by the Canadian regulations reveals that key features of U.S. pharmaceutical law should be...

Persistent link: https://www.econbiz.de/10013074086

Provision of Pharmaceuticals in Russia : Current Situation and Prospects for the Future

Avksentiev, Nikolay - 2019

An analysis of the consumption of prescription pharmaceuticals and the structure of pharmaceutical care costs has demonstrated that the availability of pharmaceuticals is still low, and that households have to pay for more than half of those costs. It has also been revealed that availability of...

Persistent link: https://www.econbiz.de/10012859587

Product patents and access to innovative medicines in a post-trips-era

Watal, Jayashree; Dai, Rong - 2019 - Manuscript date: 28 March 2019

This WTO working paper studies availability and affordability of new and innovative pharmaceuticals in a post-TRIPS era. The WTO's TRIPS Agreement (TRIPS) makes it obligatory for WTO members − except least-developed country members (LDCs) - to provide pharmaceutical product patents with a...

Persistent link: https://www.econbiz.de/10011992779

Demand Side Cost-Sharing and Prescription Drugs Utilization : Evidence from a Quasi-Natural Experiment

Hromadkova, Eva; Zdenek, Michal - 2013

In this paper we investigate the effects of introduction of lump sum copayments on the utilization of prescription drugs by elderly patients. We make use of an unique dataset and analyze the policy change that implemented patient cost-sharing in the Czech Republic starting in 2008. After the...

Persistent link: https://www.econbiz.de/10014158324

Product Patents and Access to Innovative Medicines in a Post TRIPS Era

Watal, Jayashree; DAI, Rong - 2019

This paper examines access to new and innovative pharmaceuticals in a post-TRIPS era. The WTO’s TRIPS Agreement (TRIPS) makes it obligatory for WTO members – except least-developed country members (LDCs) - to provide pharmaceutical product patents with a 20-year protection term. Developing...

Persistent link: https://www.econbiz.de/10014105991

Physician dispensing and the choice between generic and brand-name drugs : do margins affect choice?

Rischatsch, Maurus; Trottmann, Maria - 2009

prescribing behavior between physician which gain income from prescribing a specific drug and their colleagues which prescribe the … analyze the prescribing behavior of Swiss physicians using cross-sectional data between 2005 and 2007 for three important … agents. The results support our hypothesis that dispensing physicians have a higher probability of prescribing the drug with …

Persistent link: https://www.econbiz.de/10003900934

1
2
3
4
5
6
7
8
9
10
Next
Last